 |
|
New Blood Thinner May Work Without Bleeding Risk
March 27, 2007When studying a new blood thinner, one of the first signs the drug is working is seeing a slight increase in minor bleeding—nose bleeds and bruising, an inconvenient side effect of preventing the blood clots that are the leading cause of heart attack and stroke. While potentially life-saving, the drugs can also pose a risk of major bleeding in some patients, requiring frequent monitoring of blood levels.
So when he didn't see any significant increase in those typical bleeding events when studying a new blood thinner last year, UK College of Medicine cardiovascular chief David Moliterno was surprised when, at the close of the study in September, the results showed promise of significantly reducing the risk of heart attack and death with no statistical increase in major and minor bleeding events.
The drug, called a thrombin-receptor antagonist, or TRA, works in a unique way to prevent clotting by breaking down the communication between cells and proteins involved in forming clots. TRA, which is manufactured by Schering-Plough Corporation, was given in addition to established anti-clotting drugs to 1,030 patients undergoing cardiac catheterization and related intervention at 77 sites in six countries (including the United States, Canada, Italy, Belgium, Netherlands and Germany). The University of Kentucky enrolled 32 patients between August 2005 and September 2006. Patient follow-up was completed in January 2007.
"We were surprised by the extent of benefit," Moliterno said. "These results are so noteworthy because the study demonstrated that this first-in-class TRA did not increase bleeding at all in a group of patients that is certainly at risk. And honestly, therefore, we did not expect to see a large benefit. While further study is required, we observed a 46 percent lowering in serious cardiovascular events, mainly a reduction in heart attacks. This represents an early and strong efficacy signal for this novel antiplatelet compound. This is encouraging, particularly in light of the fact that this patient population requires advanced therapies and is difficult to treat."
Moliterno presented the study findings to thousands of cardiologists Saturday at the opening of the American College of Cardiology's annual scientific sessions, taking place this year in New Orleans. Moliterno and other UK Linda and Jack Gill Heart Institute cardiologists will be giving a record 26 presentations, including 10 original research study releases, at the week-long ACC scientific sessions and Innovation in Intervention: i2 Summit 2007.
University of Kentucky
"We were surprised by the extent of benefit," Moliterno said. "These results are so noteworthy because the study demonstrated that this first-in-class TRA did not increase bleeding at all in a group of patients that is certainly at risk. And honestly, therefore, we did not expect to see a large benefit. While further study is required, we observed a 46 percent lowering in serious cardiovascular events, mainly a reduction in heart attacks. This represents an early and strong efficacy signal for this novel antiplatelet compound. This is encouraging, particularly in light of the fact that this patient population requires advanced therapies and is difficult to treat."
Moliterno presented the study findings to thousands of cardiologists Saturday at the opening of the American College of Cardiology's annual scientific sessions, taking place this year in New Orleans. Moliterno and other UK Linda and Jack Gill Heart Institute cardiologists will be giving a record 26 presentations, including 10 original research study releases, at the week-long ACC scientific sessions and Innovation in Intervention: i2 Summit 2007.
University of Kentucky
Blood Thinner Current Events and Blood Thinner News RSSIncreased stroke risk from birth control pills
She was only 30 years old, but she was experiencing the classic symptoms of a stroke. Her speech suddenly became slurred, and her left hand became clumsy while eating.
Investigation of contaminated heparin syringes highlights medication safety issues
An outbreak of bloodstream infections appears to have been caused by the contamination of pre-filled heparin and saline syringes made by a single company.
Designing drugs and their antidotes together improves patient care
Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together.
Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine
Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested.
Dabigatran vs. warfarin as long-term anticoagulant therapy in atrial fibrillation
The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study (Randomized Evaluation of Long-term anticoagulant therapY).
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes
Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).
Patient safety advanced by revised heparin standards
Continuing to help ensure the identity, purity and quality of heparin, the U.S. Pharmacopeial (USP) Convention has revised written and physical standards for the widely used blood thinner.
'Artificial Golgi' may provide new insight into key cell structure
Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle.
Stanford study expands window for effective stroke treatment
Once symptoms start, there's only a tiny window of time for stroke victims to get life-saving treatment. Now, research from the Stanford University School of Medicine has cracked that window open a bit wider.
Anti-clotting drug thins risk to pregnancy and surgery patients with blood disorder
Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein. Results from a study by researchers at Yale School of Medicine and other institutions were presented December 6 at the Annual Meeting of the American Society of Hematology (ASH) in San Francisco.
More Blood Thinner Current Events and Blood Thinner News Articles
 |
The Blood Thinner Cure : A Revolutionary Seven-Step Lifestyle Plan for Stopping Heart Disease and Stroke by Kenneth R. Kensey M.D. (Author), Carol A. Turkington (Author) The Blood Thinner Cure condenses decades of medical research on heart diseases into an easy-to-understand explanation: injury-producing blood flow is what damages the arteries. The well-researched solution? Thin the blood so that it doesn't injure the arteries in the first place. Based on these results, the authors have created a simple seven-step lifestyle plan that involves regular blood donation, extra fluids, and sensible lifestyle strategies. |
 |
Aunti Mahi Poe Poe's La'au Lapa'au Tonic, Alaea, 1-Ounce Bottles (Pack of 2) by Bioponic Phytoceuticals Alaea La'au Lapa'au Tonic |
 |
The Blood Runs Thinner With Each Breath (Remix By Sickness) Wilt (Primary Contributor) |
 |
Eye for an Eye: Blood is Thinner than Gravy In the newest twist on popular courtroom drama, Kato Kaelin hosts this modern take on the criminal justice system. Each case is tried before Judge Extreme Akim. Fed up with the seemingly hopeless court system, people are demanding that the punishment fit the crime. Eye for an Eye aims to do just that, with innovative sentencing that really makes sense. Has a friend wrecked your car, and now refuses to pay for the repairs? Judge Extreme Akim may set you loose on your friends car's armed with a baseball bat! No case is too extreme's for Eye for an Eye! If you can not find justice anywhere else's Eye for an Eye may be your only hope! Eye for an Eye captures the essence of justice and puts punishment front and center. A non-traditional, no-nonsense, no-holds-barred spectacle of trial and... |
 |
Fashion Alert Medical Jewelry T-07 Blood Thinner Tag by Fashion Alert Medical Jewelry Stainless Medical ID tag. This can be worn with the medical Alert Bracelets (sold Separately) Pre-engraved Id tag. Medical Alert symbol is on front, Blood Thinner is engraved on the back. The tag is 1 ½ inches long and ½ inch high with the international medical symbol on front side. Engraving is on Back side. |
|
|
Aunti Mahi Poe Poe's La'au Lapa'au Tonic, Alaea, 1-Ounce Bottles (Pack of 2) by Bioponic Phytoceuticals Alaea La'au Lapa'au Tonic |
|
Letters.(safety of sweeteners Stevia and Splenda )(safe dietary supplements for diabetics who take blood thinners)(magnesium oxide usage)(Letter to the Editor): An article from: Women's Health Letter by Soundview Publications (Publisher) This digital document is an article from Women's Health Letter, published by Soundview Publications on January 1, 2003. The length of the article is 567 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Letters.(safety of sweeteners Stevia and Splenda )(safe dietary supplements for diabetics who take blood thinners)(magnesium oxide usage)(Letter to the Editor) Publication: Women's Health Letter (Newsletter) Date: January 1, 2003 Publisher: Soundview Publications Volume: 9 Issue: 1 Page: 8(1) Article Type: Letter to the Editor Distributed by Thomson... | |
|
Melilot - 1/4LB Bulk by Universal Naturals Melilot is considered a natural anticoagulant with blood thinning properties. | |
|
Popular acid blockers don't mix with anticlotting medication: reflux drugs might lessen protection from blood thinner.(Body & Brain): An article from: Science News by Nathan Seppa (Author) This digital document is an article from Science News, published by Science Service, Inc. on March 28, 2009. The length of the article is 528 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Popular acid blockers don't mix with anticlotting medication: reflux drugs might lessen protection from blood thinner.(Body & Brain) Author: Nathan Seppa Publication: Science News (Magazine/Journal) Date: March 28, 2009 Publisher: Science Service, Inc. Volume: 175 Issue: 7 Page: 11(1) Distributed by Gale, a part of Cengage... | |
 |
Vital Nutrients - Borage Oil 1000 mg 60 caps by Vital Nutrients Vital Nutrients - Borage Oil 1000 mg 60 caps Each capsule contains: Borage Oil (extracted without chemicals) 1000 mg. GLA (gamma linolenic acid) 240 mg. Vitamin E (natural) 10 iu Other ingredients: Gelatin, Glycerin Contains no coatings, binders, fillers, or dairy, wheat, eggs, soy, yeast, commercial sugars, starch, preservatives, or hydrogenated oil Suggested usage: Take one to two capsules daily with food or as directed by your health care professional. Warning: If pregnant, consult your physician before taking. |
| © 2009 BrightSurf.com |